ALL EYES ON GILEAD
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
A forum for researchers, students and applicants in the field of cyclodextrin technology
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
With this historical paper, prof. Stella and Dr. Rajevski wanted to honor to Dr. Thornsteinn Loftsson, Professor Emeritus at University
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Prime Minister Shinzo Abe said Monday that Japan will soon approve the SBECD-eanbled anti-viral drug remdesivir for the treatment of
Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that